synthesize

{
  "ranked_hypotheses": [
    {
      "title": "APOE4 lipid dysregulation and synaptic phagocytosis as early drivers of AD pathology requires proximal validation",
      "description": "The debate supports carrying forward APOE4 lipid dysregulation and synaptic phagocytosis as early drivers of AD pathology only if a proximal endpoint changes before the late outcome. The decisive validation path is: compare APOE4-to-APOE3 correction in neuron-microglia-astrocyte co-cultures with amyloid, lipid, and synapse engulfment readouts.",
      "target_gene": "APOE",
      "dimension_scores": {
        "evidence_strength": 0.57,
        "novelty": 0.64,
        "feasibility": 0.69,
        "therapeutic_potential": 0.58,
        "mechanistic_plausibility": 0.67,
        "druggability": 0.5,
        "safety_profile": 0.55,
        "competitive_landscape": 0.55,
        "data_availability": 0.63,
        "reproducibility": 0.66
      },
      "composite_score": 0.604,
      "evidence_for": [
        {
          "claim": "Preregistered claim: APOE4-driven lipid dysregulation and synaptic phagocytosis drive AD; converting APOE4 to APOE3 reduces amyloid and restores synaptic function",
          "source": "AD-MASTER-PLAN-APOE-20260428030754"
        }
      ],
      "evidence_against": [
        {
          "claim": "APOE genotype affects many cell types, so target conversion could rescue biomarkers without proving synaptic causality",
          "source": "AD-MASTER-PLAN-APOE-20260428030754"
        }
      ]
    },
    {
      "title": "Stratified falsifiers should govern AD Master Plan preregistration: APOE",
      "description": "Claims from this analysis should be evaluated across APOE, AD, tau, amyloid; pooled effects are insufficient when causal direction, cell state, genotype, benchmark leakage, or reproducibility risks can dominate the result.",
      "target_gene": "AD",
      "dimension_scores": {
        "evidence_strength": 0.54,
        "novelty": 0.59,
        "feasibility": 0.74,
        "therapeutic_potential": 0.5,
        "mechanistic_plausibility": 0.61,
        "druggability": 0.43,
        "safety_profile": 0.59,
        "competitive_landscape": 0.53,
        "data_availability": 0.68,
        "reproducibility": 0.7
      },
      "composite_score": 0.591,
      "evidence_for": [
        {
          "claim": "The analysis question names specific entities or evaluation structure.",
          "source": "AD-MASTER-PLAN-APOE-20260428030754"
        }
      ],
      "evidence_against": [
        {
          "claim": "The current record can still be confounded by stage, leakage, or artifact effects.",
          "source": "AD-MASTER-PLAN-APOE-20260428030754"
        }
      ]
    },
    {
      "title": "APOE should remain under review until replicated",
      "description": "The consensus is to preserve this as a debated candidate, not a canonical world-model claim. Replication or rerun evidence should precede promotion into Atlas or market funding.",
      "target_gene": "tau",
      "dimension_scores": {
        "evidence_strength": 0.52,
        "novelty": 0.55,
        "feasibility": 0.71,
        "therapeutic_potential": 0.52,
        "mechanistic_plausibility": 0.58,
        "druggability": 0.45,
        "safety_profile": 0.58,
        "competitive_landscape": 0.52,
        "data_availability": 0.65,
        "reproducibility": 0.69
      },
      "composite_score": 0.577,
      "evidence_for": [
        {
          "claim": "Concrete next test: compare APOE4-to-APOE3 correction in neuron-microglia-astrocyte co-cultures with amyloid, lipid, and synapse engulfment readouts",
          "source": "AD-MASTER-PLAN-APOE-20260428030754"
        }
      ],
      "evidence_against": [
        {
          "claim": "Promotion before replication would weaken quality control.",
          "source": "AD-MASTER-PLAN-APOE-20260428030754"
        }
      ]
    }
  ],
  "knowledge_edges": [
    {
      "source_id": "AD-MASTER-PLAN-APOE-20260428030754",
      "source_type": "analysis",
      "target_id": "APOE",
      "target_type": "entity",
      "relation": "debate_context_supports_review_of"
    },
    {
      "source_id": "AD-MASTER-PLAN-APOE-20260428030754",
      "source_type": "analysis",
      "target_id": "AD",
      "target_type": "entity",
      "relation": "debate_context_supports_review_of"
    },
    {
      "source_id": "AD-MASTER-PLAN-APOE-20260428030754",
      "source_type": "analysis",
      "target_id": "tau",
      "target_type": "entity",
      "relation": "debate_context_supports_review_of"
    },
    {
      "source_id": "AD-MASTER-PLAN-APOE-20260428030754",
      "source_type": "analysis",
      "target_id": "amyloid",
      "target_type": "entity",
      "relation": "debate_context_supports_review_of"
    }
  ],
  "synthesis_summary": "Consensus: AD Master Plan preregistration: APOE is substantive enough for debate because it names APOE4 lipid dysregulation and synaptic phagocytosis as early drivers of AD pathology and can be tied to a concrete validation path: compare APOE4-to-APOE3 correction in neuron-microglia-astrocyte co-cultures with amyloid, lipid, and synapse engulfment readouts. Dissent: APOE genotype affects many cell types, so target conversion could rescue biomarkers without proving synaptic causality. The claim should remain under review until the falsifier or replication path is executed."
}